The Honeypot Study Protocol: A Randomized Controlled Trial of Exit-Site Application of Medihoney Antibacterial Wound Gel for the Prevention of Catheter-Associated Infections in Peritoneal Dialysis Patients

Abstract

Objectives

The primary objective of this study is to determine whether daily exit-site application of standardized antibacterial honey (Medihoney Antibacterial Wound Gel; Comvita, Te Puke, New Zealand) results in a reduced risk of catheter-associated infections in peritoneal dialysis (PD) patients compared with standard topical mupirocin prophylaxis of nasal staphylococcal carriers.

Design

Multicenter, prospective, open label, randomized controlled trial.

Setting

PD units throughout Australia and New Zealand.

Participants

The study will include both incident and prevalent PD patients (adults and children) for whom informed consent can be provided. Patients will be excluded if they have had (1) a history of psychological illness or condition that interferes with their ability to understand or comply with the requirements of the study; (2) recent (within 1 month) exit-site infection, peritonitis, or tunnel infection; (3) known hypersensitivity to, or intolerance of, honey or mupirocin; (4) current or recent (within 4 weeks) treatment with an antibiotic administered by any route; or (5) nasal carriage of mupirocin-resistant Staphylococcus aureus.

Methods

370 subjects will be randomized 1:1 to receive either daily topical exit-site application of Medihoney Antibacterial Wound Gel (all patients) or nasal application of mupirocin if staphylococcal nasal carriage is demonstrated. All patients in the control and intervention groups will perform their usual exit-site care according to local practice. The study will continue until 12 months after the last patient is recruited (anticipated recruitment time is 24 months).

Main Outcome Measures

The primary outcome measure will be time to first episode of exit-site infection, tunnel infection, or peritonitis, whichever comes first. Secondary outcome measures will include time to first exit-site infection, time to first tunnel infection, time to first peritonitis, time to infection-associated catheter removal, catheter-associated infection rates, causative organisms, incidence of mupirocin-resistant microbial isolates, and other adverse reactions.

Conclusions

This multicenter Australian and New Zealand study has been designed to provide evidence to help nephrologists and their PD patients determine the optimal strategy for preventing PD catheter-associated infections. Demonstration of a significant improvement in PD catheter-associated infections with topical Medihoney will provide clinicians with an important new prophylactic strategy with a low propensity for promoting antimicrobial resistance.

Keywords

Exit-site infection honey Medihoney mupirocin peritonitis randomized controlled trial tunnel infection bacterial infection fungal infection

Get full access to this article

View all access options for this article.

References

Fried

, Abidi

, Bernardini

, Johnston

J.R.

, Piraino

Hospitalization in peritoneal dialysis patients.

Am J Kidney Dis 1999; 33: 927–33.

Mujais

Microbiology and outcomes of peritonitis in North America.

Kidney Int Suppl 2006; 103: S55–62.

Davies

S.J.

, Ogg

C.S.

, Cameron

J.S.

, Poston

, Noble

W.C.

Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD).

Perit Dial Int 1989; 9: 61–4.

Burkart

J.M.

Significance, epidemiology, and prevention of peritoneal dialysis catheter infections.

Perit Dial Int 1996; 16(Suppl 1): S340–6.

Strippoli

G.F.

, Tong

, Johnson

, Schena

F.P.

, Craig

J.C.

Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials.

Am J Kidney Dis 2004; 44: 591–603.

Piraino

, Bailie

G.R.

, Bernardini

, Boeschoten

, Gupta

, Holmes

Peritoneal dialysis-related infections recommendations: 2005 update.

Perit Dial Int 2005; 25: 107–31.

Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis.

Mupirocin Study Group.

J Am Soc Nephrol 1996; 7: 2403–8.

The CARI Guidelines.

Evidence for peritonitis treatment and prophylaxis: prophylaxis for exit site/tunnel infections using mupirocin.

Nephrology (Carlton) 2004; 9(Suppl 3): S86–90.

Annigeri

, Conly

, Vas

, Dedier

, Prakashan

K.P.

, Bargman

J.M.

Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.

Perit Dial Int 2001; 21: 554–9.

10.

Conly

J.M.

, Vas

Increasing mupirocin resistance of Staphylococcus aureus in CAPD—should it continue to be used as prophylaxis?

Perit Dial Int 2002; 22: 649–52.

11.

Perez-Fontan

, Rosales

, Rodriguez-Carmona

, Falcon

T.G.

, Valdes

Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis.

Am J Kidney Dis 2002; 39: 337–41.

12.

Cavdar

, Atay

, Zeybel

, Celik

, Ozder

, Yildiz

Emergence of resistance in staphylococci after long-term mupirocin application in patients on continuous ambulatory peritoneal dialysis.

Adv Perit Dial 2004; 20: 67–70.

13.

Bernardini

, Bender

, Florio

, Sloand

, PalmMontalbano

, Fried

Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.

J Am Soc Nephrol 2005; 16: 539–45.

14.

Cooper

R.A.

, Halas

, Molan

P.C.

The efficacy of honey in inhibiting strains of Pseudomonas aeruginosa from infected burns.

J Burn Care Rehabil 2002; 23: 366–70.

15.

Cooper

R.A.

, Molan

P.C.

, Harding

K.G.

The sensitivity to honey of gram-positive cocci of clinical significance isolated from wounds.

J Appl Microbiol 2002; 93: 857–63.

16.

Subrahmanyam

Early tangential excision and skin grafting of moderate burns is superior to honey dressing: a prospective randomised trial.

Burns 1999; 25: 729–31.

17.

Namias

Honey in the management of infections.

Surg Infect (Larchmt) 2003; 4: 219–26.

18.

Molan

P.C.

Potential of honey in the treatment of wounds and burns.

Am J Clin Dermatol 2001; 2: 13–19.

19.

Dunford

, Cooper

, Molan

Using honey as a dressing for infected skin lesions.

Nurs Times 2000; 96(14 Suppl): 7–9.

20.

Moore

O.A.

, Smith

L.A.

, Campbell

, Seers

, McQuay

H.J.

, Moore

R.A.

Systematic review of the use of honey as a wound dressing.

BMC Complement Altern Med 2001; 1: 2.

21.

Dixon

Bacteria can't resist honey.

Lancet Infect Dis 2003; 3: 116.

22.

Johnson

D.W.

, van Eps

, Mudge

D.W.

, Wiggins

K.J.

, Armstrong

, Hawley

C.M.

Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients.

J Am Soc Nephrol 2005; 16: 1456–62.

23.

Therapeutic Goods Administration. Therapeutic Goods Administration (TGA) Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) annotated with TGA comments. Available at: http://www.tga.gov.au/docs/pdf/euguide/ich/ich13595.pdf

24.

Bannerman

T.L.

, Peacock

S.J.

Staphylococcus, micrococcus, and other catalase-positive cocci. In: Murray

P.R.

, Baron

E.J.

, Jorgensen

J.H.

, Landry

M.L.

, Pfaller

M.A.

, eds. Manual of Clinical Microbiology. Washington, DC: ASM Press; 2007.

25.

The CARI Guidelines.

Evidence for peritonitis treatment and prophylaxis: prophylactic antibiotics for insertion of peritoneal dialysis catheter.

Nephrology (Carlton) 2004; 9(Suppl 3): S72–5.

26.

Twardowski

Z.J.

, Prowant

B.F.

Exit-site healing post catheter implantation.

Perit Dial Int 1996; 16(Suppl 3): S51–70.

27.

Randolph

A.G.

, Cook

D.J.

, Gonzales

C.A.

, Brun-Buisson

Tunneling short-term central venous catheters to prevent catheter-related infection: a meta-analysis of randomized, controlled trials.

Crit Care Med 1998; 26: 1452–7.

28.

Maki

D.G.

, Weise

C.E.

, Sarafin

H.W.

A semiquantitative culture method for identifying intravenous-catheter-related infection.

N Engl J Med 1977; 296: 1305–9.

29.

Clinical Laboratory and Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests. Wayne, PA: Clinical Laboratory and Standards Institute; 2006.

30.

Fuchs

P.C.

, Jones

R.N.

, Barry

A.L.

Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic.

J Clin Microbiol 1990; 28: 608–9.